SB-649,868
Drug
SB-649868 is a dual orexin receptor antagonist that was being developed by GlaxoSmithKline as a treatment for insomnia.
A phase I clinical trial evaluated doses up to 80 mg, resulting in significant improvement in sleep latency without adverse... Wikipedia